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PURPOSE. To analyze the effect of a resolvin D1 (RvD1) analogue (RvD1a) on dendritic cell
maturation, T-cell sensitization, and allograft rejection in corneal allotransplantation.
METHODS. The receptor expression of RvD1 (ALX/FPR2) on bone marrow–derived dendritic
cells (BMDC) was measured using quantitative real-time PCR. We determined BMDC
maturation after treatment with RvD1a using ELISA to measure interleukin (IL)-12 protein
expression and flow cytometry to assess the expression of CD40, major histocompatibility
complex (MHC) II, CD80, and CD86. After corneal transplantation in BALB/c mice, we
analyzed T-cell infiltration in the cornea and the draining lymph nodes using flow cytometry.
The enzyme-linked immunospot (ELISPOT) assay was used to measure T-cell sensitization via
the direct and indirect pathway. Angiogenesis and lymphangiogenesis in the cornea after
transplantation were measured using immunohistochemistry. Graft opacity and survival were
evaluated by slit lamp biomicroscopy.
RESULTS. The receptor for RvD1, lipoxin A4/formyl peptide receptor 2 (ALX/FPR2), was
expressed at a significantly lower level on immature than mature dendritic cells (DCs), and
RvD1a reduced DC expression of MHC II, CD40, and IL-12 following lipopolysaccharide (LPS)
stimulation. Using a murine model of corneal transplantation, RvD1a-treated hosts exhibited
significantly reduced allosensitization as demonstrated by decreased frequencies of interferon-
gamma–secreting T cells in the draining lymph nodes, and reduced T-cell infiltration into the
grafts. Graft survival was significantly enhanced and angiogenesis at the graft site was
suppressed in RvD1a-treated hosts compared with vehicle-treated hosts.
CONCLUSIONS. These results suggest that RvD1 inhibits DC maturation and reduces alloimmune
sensitization following transplantation, thereby establishing a novel connection between
resolvin D1 and the regulation of DC-mediated, antigen-specific immunity.
Keywords: transplant rejection, resolvin, dendritic cell
Resolvins are lipid mediators that are biosynthesized from x-3 polyunsaturated fatty acids.1 The biosynthesis of resolvins
plays an important role in resolution of acute inflammation.2
Resolvin D1 (RvD1, 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,
15E,19Z-docosahexaenoic acid) is produced via the transcellular
biosynthesis of docosahexaenoic acid [DHA] by leukocytes,
endothelial and epithelial cells,3,4 macrophages,5 and lymphoid
tissues.6 Resolvin D1 mediates potent anti-inflammatory actions
and reduces the duration and magnitude of inflammation in
complex immune-mediated diseases.7–12 Earlier, we demonstrat-
ed that RvD1 significantly suppresses innate immune responses,
including polymorphic neutrophil (PMN) infiltration and
interleukin (IL)-1 secretion following acute corneal inflamma-
tion.13 Resolvin D1 has also been shown to limit PMN
infiltration in murine peritonitis, block transendothelial migra-
tion of human PMNs, and enhance phagocytosis by human
macrophages.14–17 Although a recent report demonstrated that
RvD1 promotes clearance of allergens in asthma18 and resolvin
E1 (RvE1) reduces dendritic cell (DC) migration and IL-12
production,19,20 the function of RvD1 in adaptive immune
responses remains largely unexplored.
Resolvin D1 selectively interacts with lipoxin A4/formyl
peptide receptor 2 (ALX/FPR2) and G protein-coupled receptor
32 (GPR32) to mediate its proresolving actions.17,21 The
receptor ALX/FPR2 is commonly found on human phagocytic
cells such as dendritic cells (DCs), and its murine ortholog ALX/
FPR2 is found on macrophages,22 neutrophils,23 and DCs.24
However, the expression of ALX/FPR2 and function of RvD1 on
immature versus mature DCs has not been explored.
Dendritic cell maturation is a key factor in host allosensi-
tization and graft rejection, because of the critical function of
DCs in mediating alloimmune responses through both the
Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
www.iovs.org j ISSN: 1552-5783 5944
direct and indirect pathways of sensitization.25–27 Mature
resident and donor DCs express major histocompatibility
complex (MHC) class II, costimulatory molecules, and IL-12
after corneal transplantation, and are capable of priming host
interferon-gamma (IFN-c)–secreting Th1 cells in the draining
lymph nodes (DLNs),28,29 which are the main effector cells in
corneal allograft rejection.30–33
Herein, we aimed to investigate whether an RvD1 analogue
(RvD1a, 17R/S methyl RvD1 methyl ester) suppresses the
alloimmune response in the host through inhibition of DC
maturation. We analyzed the effect of RvD1a on DC maturation
using BMDCs in vitro, and investigated the function of RvD1a
on T-cell sensitization and allograft rejection using a mouse
model of corneal allotransplantation.
MATERIALS AND METHODS
Mice
Six- to 8-week-old male BALB/c and C57BL/6 mice (Taconic
Farms, Germantown, NY, USA) were used in all experiments.
Animals were housed in a pathogen-free environment at the
Schepens Eye Research Institute animal facility and all
procedures were approved by the Institutional Animal Care
and Use Committee. The animals were treated according to the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research.
Generation of BMDCs
Bone marrow–derived dendritic cells (BMDCs) were generated
as previously described.34 Briefly, bone marrow cells collected
from the femurs of 6- to 8-week-old C57BL/6 mice were
cultured in petri dishes at 2 3 106/10 mL RPMI-1640 medium
(Lonza Biologics, Inc., Hopkinton, MA, USA) supplemented
with 10% fetal calf serum (Atlanta Biologicals, Flower Branch,
GA, USA); 2 mM L-glutamine (Lonza Biologics, Inc.); 100 U/mL
of penicillin (Lonza Biologics, Inc.); 100 lg/mL of streptomycin
(Lonza Biologics, Inc.); 50 mM b-mercaptoethanol (Sigma-
Aldrich Corp., Springfield, MO, USA); and 200 U/mL of
granulocyte-macrophage colony-stimulating factor (GM-CSF;
PeproTech, Inc., Rocky Hill, NJ, USA). Medium was changed
every 2 days. On days 5 and 6, nonadherent and loosely
adherent immature BMDCs were harvested. To generate
mature BMDCs, we subcultured the immature BMDCs in 6-
well plates with 100 ng/mL of lipopolysaccharide (LPS; R&D
Systems, Inc., Minneapolis, MN, USA) for 24 hours. The purity
of the DCs used in the experiments was greater than 97%, as
determined by analysis of surface CD11c staining using flow
cytometry analysis. To investigate the actions of an RvD1
analogue (17[R/S] methyl- resolvin D1 methyl ester), denoted
here as RvD1a (prepared as outlined in Kasuga et al.35) on DC
function, 6 ng/mL RvD1a were added during subculture (day 6)
and LPS stimulation (day 8). Cell surface expression of CD40,
MHC II, CD80, and CD86 was analyzed using flow cytometry.
The concentration of IL-12 in the supernatants was assayed
using a commercial ELISA kit (BioLegend, San Diego, CA, USA).
Resolvin D1a was synthesized as outlined in Kasuga et al.35 and
Sun et al.36
RNA Isolation and Real-Time PCR
Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA,
USA) and commercial spin columns (RNeasy MinElute Spin
Columns; Qiagen, Valencia, CA, USA) as previously de-
scribed.37 Reverse transcription of total RNA was conducted
using oligo(dT) primer and reverse transcriptase (Superscript
III Reverse Transcriptase; Invitrogen). An amount of 1 lL of
total cDNA, synthesized from 400 ng of total RNA with random
hexamers, was loaded in each well, and assays were performed
in triplicates. Real-time qPCR was performed with a commer-
cial master mix (Taqman Universal PCR Mastermix; Applied
Biosystems, Foster City, CA, USA) and FAM-MGB dye-labeled
predesigned primers (Applied Biosystems) for ALX/Fpr2
(Mm00484464_s1). Polymerase chain reaction was performed
for 2 minutes at 508C and 10 minutes at 958C, followed by 35
cycles of 15 seconds at 958C and 1 minute at 608C, using a
sequence detection system (ABI PRISM 7900 HT; Applied
Biosystems). Amplification of PCR of the housekeeping gene
encoding Gapdh (Mm999999915_gl) was used as internal
control. A nontemplate control was included in all experi-
ments to evaluate DNA contamination of isolated RNA and
reagents. The results were analyzed by the comparative
threshold cycle (CT) method.
Orthotropic Corneal Transplantation and
Assessment of Graft Survival
The procedures for corneal orthotropic transplantation, in
which corneal grafts from C57BL/6 (H-2b) mice were
transplanted onto BALB/c (H-2d) recipient mice, have been
well-established and described previously.38,39 Briefly, central
2-mm diameter corneal grafts were excised from C57BL/6 mice
with a trephine and micro-scissors (Storz Instrument Co., St.
Louis, MO, USA). The recipient beds were prepared by excising
1.5 mm pieces of tissue from the central cornea of BALB/c host
mice. Prepared donor corneal grafts were then transplanted
onto the host beds with eight interrupted 11-0 nylon sutures.
The sutures were removed 7 days post transplantation.
A total of 100 lL RvD1a (1 lg/mL) or vehicle (0.01% ethanol
with normal saline) were injected intravenously into the
recipient mice on days 0 and 7 post transplantation as
previously described.40,41 The RvD1 analogue 17R/s methyl
was prepared as previously described,36 and its structural
integrity was assessed prior to experiments using published
criteria.42 All grafts were evaluated using slit-lamp biomicros-
copy weekly up to 8 weeks. Grafts were defined as rejected
when they became opaque and the iris details could not be
recognized (score >2 according to a standardized opacity-
grading scheme of 0–5).38
Cell Isolation and Flow Cytometry Analysis
To obtain single-cell suspensions from corneas, corneal tissue
samples were digested in 2 mg/mL collagenase D at 378C, as
previously described.43 Other single-cell suspensions were
obtained from ipsilateral DLNs (submandibular and cervical) or
from in vitro BMDC cultures. Non-specific staining was
blocked with an anti-FcR antibody (R&D Systems), then cells
were incubated with the following antibodies: fluorescein
isothiocyanate (FITC)-conjugated murine anti-CD3 (BD Phar-
mingen, San Jose, CA, USA), anti-CD40, anti-CD80, anti-CD86,
anti-IAb (MHC II), or phycoerythrin (PE)-conjugated anti-
CD11c antibodies (BD Pharmingen). Prior to intracellular
IFN-c staining, cells were stimulated for 4 hours with phorbol
12-myristate 13-acetate (PMA; Sigma-Aldrich Corp.) and ion-
omycin (Sigma-Aldrich Corp.) in the presence of GolgiStop (BD
Biosciences, Franklin Lakes, NJ, USA), and subsequently stained
with a FITC-conjugated anti-CD3 antibody (BioLegend). After
fixation and permeablization (buffers from eBioscience, Inc.,
San Diego, CA, USA), cells were stained with a PE-conjugated
IFN-c antibody (BD Pharmingen) for 30 minutes in staining
buffer at 48C. The cells were thoroughly washed and analyzed
via flow cytometry (EPICS XL; Beckman Coulter, Brea, CA,
USA). All experiments were conducted with parallel staining
with respective isotype controls (primary antibodies and
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isotype controls were purchased from eBioscience, Inc., unless
noted otherwise).
ELISPOT Assay
The enzyme-linked immunospot assay was performed to
measure the frequencies of directly and indirectly primed T
cells, as described previously.43 Briefly, 96-well ELISPOT plates
(Whatman Polyfiltronics, Newton, MA, USA) were coated with
4 lg/mL primary anti–IFN-c mAb (BD Pharmingen) in sterile
PBS overnight. Then, the plates were washed and blocked for
1.5 hours with PBS containing 1% bovine serum albumin and
cells were added to these plates. Purified T cells (5 3 105
CD90.2-positive magnetic activated cells [MACS]–sorted) from
the DLNs of the grafted BALB/c mice (eight of each group, 3
weeks post transplantation of C57BL/6 donor corneas) were
pooled and then incubated in triplicates with C57BL/6 antigen-
presenting cells (APCs; 53 105 CD90.2-negative, MACS-sorted
splenocytes) for 48 hours to quantify frequencies of directly
allosensitized T cells. To quantify frequencies of indirectly
allosensitized T cells, syngeneic (BALB/c) APCs (1 3 106)
pulsed with sonicated donor antigen (2 3 107 C57BL/6 APCs/
mL) were incubated with BALB/c recipients’ T cells; T cells
harvested from lymph nodes of naive BALB/c animals served as
controls. After washing, biotinylated anti–IFN-c detection mAb
was added at 2 lg/mL (BD Pharmingen) and incubated
overnight at 48C. The plates were then washed, incubated
for 1 hour with avidin-HRP and developed using amino-
ethylcarbazole staining solution (Sigma-Aldrich Corp.). The
resulting spots were analyzed using the computer-assisted
ELISPOT image analyzer (Cellular Technology Ltd., Cleveland,
OH, USA).
Corneal Wholemount and Immunofluorescent
Staining
Freshly excised corneas were washed in phosphate-buffered
saline, fixed in acetone for 15 minutes, and then double stained
with CD31 and lymphatic vessel endothelial hyaluronan
receptor (LYVE)-1 as described previously44 using goat anti–
mouse CD31 FITC as a panendothelial marker (Santa Cruz
Biotechnology, Dallas, TX, USA), diluted 1:100; and purified
rabbit anti–mouse LYVE-1 as a lymphatic endothelial marker
(Abcam, Inc., Cambridge, MA, USA), diluted 1:400. Rhodamine-
conjugated goat anti-rabbit (BD Pharmingen, 1:100) was used
as a secondary antibody.
Statistical Analysis
Dunnett’s multiple comparison tests and ANOVA or Student’s t-
test were applied for the data analysis. Kaplan-Meier survival
curves were analyzed in a log-rank (Mantel-Cox) test. Results
are presented as the mean 695% confidence interval (CI), and
error bars represent the 95% CI. Values of P  0.05 were
considered statistically significant.
RESULTS
RvD1a Inhibits LPS-Induced BMDC Maturation
We first investigated the gene expression level of the RvD1
receptor ALX/Fpr2 on both DCs and T cells. We cultured
BMDCs for up to 6 days in the presence of GM-CSF to obtain
immature DCs, then LPS was added for 24 hours to generate
FIGURE 1. Resolvin D1 analogue inhibits LPS-induced BMDC maturation. (A) Quantitative RT-PCR analysis showing ALX/Fpr2 mRNA expression in
immature DCs (imDC) and mature DCs (mDC; 1495.6 6 110.0 vs. 588.8 6 11.5, n¼3, P¼0.008); P values were calculated using the Student’s t-test
and error bars represent mean 6 SEM. Data shown are representative of three independent experiments. (B) The concentration of IL-12p70 in
culture supernatant was measured 24 hours after LPS stimulation in RvD1a and vehicle-treated BMDCs using ELISA (216.0 6 9.1 vs. 168.2 6 3.2, n¼
4, P¼ 0.0025, t-test). (C) Gating on CD11c-positive cells, the expression of CD40, MHC II, CD80, and CD86 in RvD1a- and vehicle-treated BMDCs
were measured by flow cytometry. We cultured BMDCs from days 0 to 6 and treated with 6 ng/mL RvD1a on days 6 and 8. Lypolysaccharide was
added to stimulate maturation on day 8 for 24 hours. Data shown are representative of three independent experiments.
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mature DCs. Real-time PCR was performed showing that ALX/
Fpr2 is expressed 2.5-fold higher on immature DCs than
mature DCs (Fig. 1A). However, no ALX/Fpr2 expression was
detectable in T cells isolated from DLNs of either na¨ıve or
grafted mice 3 weeks after allogeneic corneal transplantation
(data not shown). Since anti-murine ALX/FPR2 antibody is not
commercially available, we were unable to assess its protein
expression. To investigate the functional effect of RvD1a on DC
maturation, BMDCs were stimulated with LPS on day 8 and
treated with 6 ng/mL RvD1a or vehicle on days 6 and 8.
Twenty-four hours after LPS addition, we analyzed the
supernatant using ELISA and observed a significant lower IL-
12 concentration in RvD1a-treated BMDCs compared with the
vehicle-treated cells. Gating on CD11c positive cells, flow
cytometry analysis revealed that RvD1a treatment reduces the
frequencies of CD40þ (63.1% vs. 79.0% vehicle) and MHC IIþ
(68.5% vs. 85.0% vehicle) by approximately 20% compared
with the vehicle-treated BMDCs. However, RvD1a treatment
did not significantly alter the expression of CD80þ and CD86þ
on BMDCs (Fig. 1C).
RvD1a Inhibits Host T-Cell Allosensitization
Through Both Direct and Indirect Pathways
Interferon gamma–producing T cells are the principal media-
tors of acute corneal allograft rejection. Following corneal
transplantation, both CD4þ and CD8þ T cells are activated and
have the ability to reject allograft.45 Therefore, we determined
the frequencies of total IFN-c producing CD4þ as well as CD8þ
T cells in the DLNs 3 weeks after transplantation using CD3þ,
CD4þ, CD8þ, and IFN-c costaining. We observed significantly
decreased frequencies of IFN-cþ CD4 T cells among total CD3þ
T cells in the RvD1a treated group compared the vehicle-
treated group. Frequencies of IFN-cþCD8 T cells were lower in
RvD1a treated mice compared with vehicle-treated mice,
however not significantly (Fig. 2A).
Given that host T cells are allosensitized either directly by
donor APCs or indirectly by host APCs, we further investigated
the frequencies of directly or indirectly primed of IFN-c
producing T cells using the ELISPOT assay. In the RvD1a-
treated group, the frequency of allosensitized T cells in the
host DLNs were significantly lower in both direct (746 6 21 vs.
FIGURE 2. Resolvin D1 analogue treatment suppresses host T-cell allosensitization. Allografted BALB/c mice were treated intravenously with 100 ng
RvD1a or vehicle on days 0 and 7 post transplantation. Mice were analyzed 21 days post transplantation. (A) Flow cytometry analysis of IFN-c
expressing CD4þ and CD8þ T cells among CD3þ T cells in the draining lymph nodes from RvD1a- and vehicle-treated host DLNs 3 weeks post
transplantation is shown (representative plot, 500,000 events/sample). CD4þIFN-cþ: 2.4% 6 0.4% vehicle versus 1.1% 6 0.5% RvD1a treated, n¼ 8,
**P¼0.009); CD8þIFN-cþ: 1.9 6 0.4% vehicle versus 1.6% 6 0.2% RvD1a treated, n¼8, ns). (B) ELISPOT assay shows IFN-cþT cells primed by either
donor (direct) or host (indirect) APCs. Direct pathway (T cells stimulated by C57BL/6 splenic APCs), vehicle 988 6 54 versus RvD1a 746 6 21
spots/106 T cells, n ¼ 8, *P ¼ 0.014; indirect pathway (stimulated by BALB/c splenic APCs and sonicated with C57BL/6 antigen), vehicle 43 6 6
versus RvD1a 24 6 4 spots/106 T cells, n¼ 8, *P¼ 0.048; P values were calculated using the Student’s t-test and error bars represent mean 6 SEM.
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988 6 54 spots/106 T cells, P¼ 0.014) and indirect (24 6 4 vs.
43 6 6 spots/106 T cells, P¼ 0.048) pathways, compared with
the respective vehicle groups (Fig. 2B).
RvD1a Inhibits Graft T-Cell Infiltration, Graft
Angiogenesis, and Promotes Corneal Allograft
Survival
Systemic RvD1a administration led to a 22% reduction of host
T-cell recruitment into the grafts compared with the control
group 3 weeks post transplantation (Fig. 3A). Graft bed
vascularity is the leading risk factor for allorejection in corneal
transplantation.46 Thus, we examined the angiogenic and
lymphangiogenic response after transplantation using biomi-
croscopy weekly for up to 8 weeks. Over the 8-week
observation period, the graft angiogenesis score was consis-
tently lower in the RvD1a-treated than in the vehicle-treated
group (Fig. 3B). In addition, we examined the blood (CD31þ)
and lymphatic vessels (LYVE-1þ) of the grafted corneas using
immunofluorescence staining 21 days after transplantation
(Fig. 3C). Quantification of the vascularized areas in corneal
wholemounts showed that RvD1a treatment significantly
reduced the de novo generation of CD31high LYVE-1 blood
vessels as well as CD31low LYVE-1high lymphatic vessels (CD31:
7.6% 6 0.8% vs. 12.9% 6 1.6%, n ¼ 6, P < 0.00001; LYVE-1:
6.5% 6 1.0% vs. 11.1% 6 1.4%, n ¼ 6, P < 0.00001; Figs. 3D,
3E) compared with vehicle-treated mice. Finally, graft opacity
scores were significantly lower (Fig. 3F) and graft survival (%)
was significantly higher in RvD1a-treated mice compared with
the vehicle-treated control mice (graft survival: 76.9% in the
RvD1a-treated group, 37.5% in the controls; log-rank analysis, n
¼ 16, P ¼ 0.02; Fig. 3G).
DISCUSSION
In the current study, using a stable analogue of the proresolv-
ing mediator RvD1, we investigated its actions on in vitro
generated BMDCs as well as its effect on alloantigen-specific
T-cell responses in an in vivo model of corneal transplantation.
Previous studies have demonstrated that RvD1 plays a
prominent role in resolving acute inflammation through
reduced neutrophil recruitment, enhancing phagocytosis, and
reducing cytokine secretion in corneal angiogenesis, vascular
inflammation, and pulmonary inflammation.13,17,47,48 The
importance of ALX/Fpr2 in mediating the anti-inflammatory
functions of RvD1 has previously been demonstrated.17,49
Recently, the receptor ALX/FPR2 was found to mediate RvD1
actions in human phagocytes,16 and evoke homeostatic tissue
functions of RvD1 in resolution through specific proresolving
microRNAs.21 In human monocytes, ALX/FPR2 (also known as
FPRL1) is downregulated as they differentiate into DCs.50 We
demonstrate here that there is a 60% reduction in the
expression of ALX/Fpr2 in LPS-stimulated mature murine
BMDCs (Fig. 1A), suggesting that RvD1 may primarily affect
immature BMDCs and that furthermore, the expression level of
ALX/FPR2 on DCs may be functionally relevant. In contrast, the
mRNA expression of ALX/Fpr2 in both na¨ıve and primed T
cells was undetectable (data not shown), indicating that RvD1
may not have a direct effect on T cells. We additionally found
that RvD1a-treated BMDCs displayed reduced expression of
MHC II, CD40, and IL-12p70 (Figs. 1B, 1C). Our results are in
line with previous studies using DHA, arachidonic acid, and
eicosapentaenoic acid to inhibit maturation of LPS-stimulated
BMDC cultures.51,52 Docosahexaenoic acid has been shown to
effectively suppress IL-12 production by DCs.51 However, the
expression of CD80/CD86 costimulatory molecules was not
significantly changed, suggesting that RvD1 may modulate DC–
T-cell interactions through the CD40-CD154 pathway, but not
through the CD80/86-CD28 pathway. Both MHC II and CD40
are critical for T-cell sensitization after corneal transplanta-
tion,53 which suggests that RvD1 may indirectly affect the graft
survival through maintaining the low maturation state of DCs.
Similar results were reported for another member of the
resolvin family, RvE1. Dendritic cells treated in vitro with RvE1
maintained an immature phenotype because RvE1 prevents
upregulation of maturation markers as well as costimulatory
molecules and reduces IL12p70 production.19,20 The original
RvE1 structural assignment of stereochemistry and total
organic synthesis showed that this action of RvE1 is similar
to LXA4 and its receptor ALX on PMNs.
19 These data support
our findings that RvD1 regulates inflammation and adaptive
immune response through ALX on DCs.
Although the actions of RvD1 on DCs and T cells are not yet
studied,54 the RvD1 precursor DHA leads to reduction of
costimulatory molecules and cytokine production in human
monocyte-derived DCs and murine BMDCs.51,55–57 Dendritic
cells treated with DHA show reduced ability to activate naive T
cells to differentiate into Th1/Th17 effectors in an experimen-
tal encephalitis model.58 Previous data have shown that IFN-c
secreting T cells,31 especially the Th1 cells, play a key role in
corneal allograft rejection.45,59 In corneal transplantation, the
allograft rejection is mediated by adaptive immunity, whereas
innate immune responses conducted by PMNs and macro-
phages may contribute to the nonspecific inflammation.
However, these innate cells are not responsible for graft
rejection upon alloantigen recognition. Nevertheless, previous
data showed that RvD1 acts on human PMNs and macrophages
in vitro and regulates their trafficking and functions in many in
vivo mouse and rabbit models.2,8,15,16 These effects may
reduce nonspecific inflammation in the host microenviron-
ment; some innate cells also play a role as APCs and thus
indirectly contribute to the suppression of adaptive alloim-
mune response to the graft, although the principal APCs in
corneal allograft transplantation are DCs.60 Accordingly, we
show herein that RvD1a treatment reduces not only the IFN-cþ
CD4 and CD8 T-cell differentiation in the DLNs (Fig. 2A), but
also suppressed CD3þ T-cell infiltration into the graft (Fig. 3A),
demonstrating that RvD1a effectively inhibits allosensitization.
As a result, we observed improved opacity scores and higher
graft survival rates in the RvD1a-treated group compared with
the vehicle-treated group (Figs. 3F, 3G).
Both donor- and host-derived DCs are able to sensitize T
cells, via the direct and indirect pathways, respectively.31 Thus,
we used the ELISPOT assay to differentiate between both
pathways, and found both pathways to be impaired after
RvD1a treatment (Fig. 2B), suggesting that RvD1a actions are
not dependent on the origins (donor versus host) of DCs, and
are not strain-specific.
The normal cornea is both alymphatic and avascular.61
However, corneal lymphangiogenesis significantly enhances
the trafficking of graft antigens and alloantigen-bearing APCs to
the DLNs,33 while corneal angiogenesis significantly promotes
effector T-cell trafficking to the graft.62,63 In addition to its
effects on DC function and sensitization, we demonstrate here
that RvD1a treatment significantly reduced the extent of
angiogenesis and lymphangiogenesis after corneal grafting
(Figs. 3B–E). Our current data are in accord with the results
of a previous study applying RvD1 locally in a suture-induced
neovascularization model.13 Thus, we speculate that in
addition to its suppressive effect on allosensitization through
downregulation of DC maturation, RvD1 and its stable
analogue may also suppress alloimmunity via inhibition of
local angiogenic responses.
In summary, we demonstrate here, for the first time, that
RvD1a inhibits DC maturation and that systemic application of
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FIGURE 3. Resolvin D1 analogue promotes corneal allograft survival by suppressing graft T-cell infiltration and angiogenesis. Allografted BALB/c
mice were treated systemically with 100 ng RvD1a or vehicle on days 0 and 7 post transplantation. (A) Flow cytometry analysis shows the
frequencies of CD3þ T cells among the total digested corneal cells from the RvD1a- and vehicle-treated hosts 21 days post transplantation. Corneas
were harvested and digested in collagenase D at 378C to obtain a single cell suspension. The frequencies of infiltrated CD3þ T cells in the cornea
were reduced in RvD1a-treated mice compared to vehicle-treated mice (pooled sample n¼ 8/group, total events 50,000/sample). Data shown are
representative for three independent experiments. (B) Corneal graft angiogenesis was scored biomicroscopically in a masked fashion with a slit
lamp according to a standardized scoring grid. Scores in the RvD1a-treated group were significantly lower compared with the vehicle group (Two-
way ANOVA with Bonferroni posttest, n¼ 8, P < 0.0001). (C) Representative epifluorescence micrographs display whole corneas from na¨ıve and
RvD1a-treated as well as vehicle-treated hosts (n¼ 6/group). Tissues were harvested 21 days post transplantation and stained with anti-CD31 Ab
(green) and anti-LYVE-1 Ab (red;34 magnification). (D, E) The percentage of the corneal area covered with blood vessels (CD31high/LYVE-1) 7.6%
6 0.8% RvD1-treated versus 12.9% 6 1.6% vehicle-treated, n ¼ 6, P < 0.00001 one-way ANOVA with Tukey’s posttest (D) and lymphatic vessels
(CD31low/LYVE-1high) 6.5% 6 1.0% vs. 11.1% 6 1.4%, n ¼ 6, P < 0.00001 (E) of the total cornea. Representative data from three independent
experiments are shown. (F) Graft opacity scores of RvD1a-treated and vehicle-treated mice (two-way ANOVA with Bonferroni posttest, n¼8, ***P <
0.0001). (G) Kaplan-Meier graft survival curve of allografted BALB/c hosts treated with 100 ng RvD1a intravenously once a week for up to 8 weeks
after corneal transplantation (log-rank analysis n ¼ 8, *P ¼ 0.02).
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RvD1a significantly increased corneal allograft survival. In-
creased graft survival is associated with reduced host T-cell
allosensitization, graft T-cell infiltration, and corneal angiogen-
esis. The proresolving mediator RvD1a may thus serve as a
novel therapeutic for controlling alloimmunity after corneal
transplantation.
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